Global Humira Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Humira Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Humira (adalimumab) is a tumor necrosis factor (TNF) blocker that reduces the effects of a substance in the body that can cause inflammation.
Humira is used to treat many inflammatory conditions in adults, such as ulcerative colitis, Rheumatoid Arthritis, psoriatic arthritis, Ankylosing Spondylitis, plaque psoriasis, and a skin condition called hidradenitis suppurativa.
Humira is also used in adults and children to treat Crohn's disease or juvenile idiopathic arthritis.
In 2014, in India, the first adalimumab biosimilar came to market at a price of $200. Two years later, another Indian drugmaker, Torrent Pharmaceuticals, launched a second biosimilar. Humira's U.S. patent expired in 2016.
Humira report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Humira market is projected to reach US$ 9235.6 million in 2034, increasing from US$ 17070 million in 2022, with the CAGR of -8.3% during the period of 2024 to 2034. Demand from Ankylosing Spondylitis and Rheumatoid Arthritis are the major drivers for the industry.
The classification of Humira includes Humira Syringe and Humira Pen. The proportion of Humira Syringe is about 78%.
Humira is widely used for Ankylosing Spondylitis, Rheumatoid Arthritis, Crohn’s disease and other disease. The most proportion of Humira is for Ankylosing Spondylitis, and the proportion is about 43%.
USA is the largest market, with a sales market share nearly 65%. Following USA, Europe is the second largest market with the sales market share of 30%.
Market competition will intense. AbbVie, Eisai, Cadila Healthcare, Torrent Pharmaceuticals, Amgen and Boehringer Ingelheim are the key manufacturters of Humira. AbbVie is the leader of this industry by 97% market shares.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Humira market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
AbbVie
Eisai
Cadila Healthcare
Torrent Pharmaceuticals
Amgen
Boehringer Ingelheim
Segment by Type
Humira Syringe
Humira Pen
Ankylosing Spondylitis
Rheumatoid Arthritis
Crohn’s Disease
Others
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Humira market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Humira, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Humira industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Humira in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Humira introduction, etc. Humira Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Humira market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Humira is used to treat many inflammatory conditions in adults, such as ulcerative colitis, Rheumatoid Arthritis, psoriatic arthritis, Ankylosing Spondylitis, plaque psoriasis, and a skin condition called hidradenitis suppurativa.
Humira is also used in adults and children to treat Crohn's disease or juvenile idiopathic arthritis.
In 2014, in India, the first adalimumab biosimilar came to market at a price of $200. Two years later, another Indian drugmaker, Torrent Pharmaceuticals, launched a second biosimilar. Humira's U.S. patent expired in 2016.
Humira report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Humira market is projected to reach US$ 9235.6 million in 2034, increasing from US$ 17070 million in 2022, with the CAGR of -8.3% during the period of 2024 to 2034. Demand from Ankylosing Spondylitis and Rheumatoid Arthritis are the major drivers for the industry.
The classification of Humira includes Humira Syringe and Humira Pen. The proportion of Humira Syringe is about 78%.
Humira is widely used for Ankylosing Spondylitis, Rheumatoid Arthritis, Crohn’s disease and other disease. The most proportion of Humira is for Ankylosing Spondylitis, and the proportion is about 43%.
USA is the largest market, with a sales market share nearly 65%. Following USA, Europe is the second largest market with the sales market share of 30%.
Market competition will intense. AbbVie, Eisai, Cadila Healthcare, Torrent Pharmaceuticals, Amgen and Boehringer Ingelheim are the key manufacturters of Humira. AbbVie is the leader of this industry by 97% market shares.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Humira market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
AbbVie
Eisai
Cadila Healthcare
Torrent Pharmaceuticals
Amgen
Boehringer Ingelheim
Segment by Type
Humira Syringe
Humira Pen
Segment by Application
Ankylosing Spondylitis
Rheumatoid Arthritis
Crohn’s Disease
Others
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Humira market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Humira, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Humira industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Humira in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Humira introduction, etc. Humira Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Humira market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices